Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2021 12:12 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.

- SIVEXTRO now available under Nabriva’s National Drug Code - 100% of SIVEXTRO’s net product sales to be recorded by Nabriva DUBLIN, Ireland and FORT WASHINGTON, Pa., April 15, 2021 (GLOBE...
April 02, 2021 16:01 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
April 01, 2021 08:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
March 16, 2021 08:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)

-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral...
March 11, 2021 16:07 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Updates

-Relaunched XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with...
March 03, 2021 16:05 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics to Report 2020 Financial Results and Recent Corporate Highlights on March 11, 2021

DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
March 01, 2021 08:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and...
February 26, 2021 08:00 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
February 23, 2021 07:00 ET | Source: Nabriva Therapeutics US, Inc

Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial Pneumonia (CABP) Treatment Guidelines

Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country Macrolide resistance shown to be significantly...
February 01, 2021 16:30 ET | Source: Nabriva Therapeutics US, Inc

Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...